Figure 1.
Figure 1. Phenotype of leukocyte cone–derived ILC populations (A) Gating strategy used to purify ILC1s, ILC2s, and ILC3s from peripheral blood, in comparison with fluorescence minus one control controls, following pre-enrichment with NK combo protocol. Dot plots are representative of >10 independent experiments (n = 2 donors/experiment). (B) Differential expression of CD161 across the 3 ILC populations as depicted by a representative histogram. (C) Graph representative of the percentages of CD161+ and CD161− populations for each of the ILC types. Data are shown as mean of the population; each dot represents 1 donor. FITC, fluorescein isothiocyanate; FMO, fluorescence minus one; FSC, forward scatter; SSC, side scatter.

Phenotype of leukocyte cone–derived ILC populations (A) Gating strategy used to purify ILC1s, ILC2s, and ILC3s from peripheral blood, in comparison with fluorescence minus one control controls, following pre-enrichment with NK combo protocol. Dot plots are representative of >10 independent experiments (n = 2 donors/experiment). (B) Differential expression of CD161 across the 3 ILC populations as depicted by a representative histogram. (C) Graph representative of the percentages of CD161+ and CD161 populations for each of the ILC types. Data are shown as mean of the population; each dot represents 1 donor. FITC, fluorescein isothiocyanate; FMO, fluorescence minus one; FSC, forward scatter; SSC, side scatter.

Close Modal

or Create an Account

Close Modal
Close Modal